Skip to main content

Table 4 Toxic effects occurring during treatment of advanced breast cancer with PLD (described in at least 2 PLD-treated patients).

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Toxic effects

N (%)

PPE

22 (17)

   Grade 1

11 (9)

   Grade 2

9 (7)

   Grade 3

1 (1)

Exanthema

18 (14)

Mucositis

16 (12)

Nausea/Vomiting

12 (9)

Fatigue

11 (9)

Infectious event

12 (9)

Alopecia (only grade 1 and 2)

7 (5)

Gastrointestinal problems

6 (5)

Respiratory problems

5 (4)

Cardiac problems*

5 (4)

Neutropenia grade 4

3 (2)

Thrombocytopenia grade 4

2 (2)

Thromboembolic event

2 (2)

Cough

2 (2)

Hypersensitivity reaction

2 (2)

  1. *Including 2 patients with severe congestive heart failure, one case of which was fatal. 4 patients with cardiac adverse events during PLD therapy harboured 2 cardiac risk factors, whereas the one patient with fatal exacerbation of heart failure was characterized by 5 cardiac risk factors.